Krystal Biotech Markedsverdi 2024

Hva gjør Krystal Biotech?

Krystal Biotech Inc was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company specializes in the development and commercialization of gene therapy products. It has several divisions, including dermatological and musculoskeletal diseases, as well as Ebenezer and X-Linked Retinoschisis. In the history of the company, there have been several milestones. In 2017, the company completed its first financing round, raising $8 million. In the same year, it became the first company to successfully treat a patient with its gene therapy for epidermolysis bullosa. This was a major breakthrough as this disease is otherwise difficult to treat. In 2018, the company went public on the Nasdaq, raising over $50 million. In 2019, Krystal Biotech began developing a gene therapy product for hereditary angioedema. The company's business model is primarily based on the discovery and development of gene therapy products targeting genetic defects. The goal is to treat diseases that are otherwise difficult or impossible to treat. Krystal Biotech emphasizes that it follows a patient-centric approach in the development of its gene therapy products. Another part of the business model is collaborating with partner companies and institutions to advance the development and commercialization of its products. Krystal Biotech Inc has several divisions. The first division focuses on dermatological diseases. Its gene therapy products are designed to treat epidermolysis bullosa and Netherton syndrome. Epidermolysis bullosa is a rare disease caused by a mutation in collagen and other proteins, leading to blistering and lesions on the skin. Netherton syndrome is a disease that can also cause skin rashes and allergic reactions. Krystal Biotech offers gene therapy products to reduce the symptoms of these diseases and improve patients' quality of life. Another division is musculoskeletal diseases. Krystal Biotech Inc has developed gene therapy products to treat patients with osteoarthritis and sickle cell anemia. Osteoarthritis is a painful condition caused by the breakdown of cartilage in the joint. The gene therapy products offered by Krystal Biotech are intended to promote the regeneration of cartilage cells and support joint preservation. Sickle cell anemia is an inherited disease that causes red blood cells to have an abnormal shape and can block blood vessels. Krystal Biotech's gene therapy products are intended to reduce the risk of painful crises caused by this condition. Another division of Krystal Biotech is Ebenezer and X-Linked Retinoschisis. This is an inherited condition that affects vision. Krystal Biotech has developed gene therapy products to treat this problem. Overall, Krystal Biotech Inc has conducted promising research projects. The company has core expertise in gene therapy and can apply its innovations to various medical fields. The gene therapy products offered by Krystal Biotech are intended to improve patients' lives and treat diseases that are otherwise difficult to cure. Krystal Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.